MA55064A - Composés utilisés comme inhibiteurs de kinase - Google Patents
Composés utilisés comme inhibiteurs de kinaseInfo
- Publication number
- MA55064A MA55064A MA055064A MA55064A MA55064A MA 55064 A MA55064 A MA 55064A MA 055064 A MA055064 A MA 055064A MA 55064 A MA55064 A MA 55064A MA 55064 A MA55064 A MA 55064A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitors
- compounds used
- compounds
- kinase
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1522245.8A GB201522245D0 (en) | 2015-12-16 | 2015-12-16 | Compounds useful as kinase inhibitors |
GBGB1613945.3A GB201613945D0 (en) | 2016-08-15 | 2016-08-15 | Compounds useful as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55064A true MA55064A (fr) | 2021-09-29 |
Family
ID=57590725
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49809A MA49809A1 (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
MA055064A MA55064A (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49809A MA49809A1 (fr) | 2015-12-16 | 2016-12-16 | Composés utilisés comme inhibiteurs de kinase |
Country Status (36)
Country | Link |
---|---|
US (7) | US10695323B2 (fr) |
EP (2) | EP3782994A1 (fr) |
JP (3) | JP6731483B2 (fr) |
KR (2) | KR20210018530A (fr) |
CN (9) | CN114634447A (fr) |
AU (4) | AU2016373530B2 (fr) |
CA (1) | CA3008488C (fr) |
CL (1) | CL2018001591A1 (fr) |
CO (1) | CO2018006164A2 (fr) |
CR (1) | CR20180367A (fr) |
CY (1) | CY1123561T1 (fr) |
DK (1) | DK3390395T3 (fr) |
EA (1) | EA035132B1 (fr) |
ES (1) | ES2828431T3 (fr) |
FI (1) | FIC20240004I1 (fr) |
FR (1) | FR24C1009I1 (fr) |
HK (1) | HK1263254A1 (fr) |
HR (1) | HRP20201835T1 (fr) |
HU (2) | HUE051921T2 (fr) |
IL (4) | IL285976B2 (fr) |
LT (1) | LT3390395T (fr) |
MA (2) | MA49809A1 (fr) |
MD (1) | MD3390395T2 (fr) |
MX (2) | MX2021003478A (fr) |
NL (1) | NL301262I2 (fr) |
NZ (1) | NZ743553A (fr) |
PE (3) | PE20220502A1 (fr) |
PH (1) | PH12018501268A1 (fr) |
PT (1) | PT3390395T (fr) |
RS (1) | RS60982B1 (fr) |
SG (2) | SG10202012498TA (fr) |
SI (1) | SI3390395T1 (fr) |
TN (1) | TN2018000213A1 (fr) |
UA (2) | UA127863C2 (fr) |
WO (1) | WO2017103611A1 (fr) |
ZA (4) | ZA201804137B (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
AU2016322063A1 (en) | 2015-09-16 | 2018-04-12 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
CA3008488C (fr) * | 2015-12-16 | 2023-10-10 | Loxo Oncology, Inc. | Composes utilises comme inhibiteurs de kinase |
GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
MX2020010469A (es) * | 2018-04-06 | 2021-04-19 | Praxis Biotech LLC | Inhibidores del atf6 y sus usos. |
WO2019220962A1 (fr) * | 2018-05-18 | 2019-11-21 | 富士フイルム株式会社 | Procédé de production d'un composé 3-difluorométhylpyrazole, procédé de production d'un composé d'acide 3-difluorométhylpyrazole-4-carboxylique, et composé de pyrazolidine |
AU2019314302A1 (en) * | 2018-07-31 | 2021-01-28 | Loxo Oncology, Inc. | Spray-dried dispersions and formulations of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1H-pyrazole-4-carboxamide |
WO2021028645A1 (fr) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
WO2021053234A1 (fr) * | 2019-09-19 | 2021-03-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Composés et compositions pour le traitement d'une maladie rénale |
CN110724135B (zh) * | 2019-11-18 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种艾拉普林中间体及其制备方法 |
US20230041515A1 (en) * | 2019-12-06 | 2023-02-09 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
US20230145305A1 (en) * | 2020-03-12 | 2023-05-11 | Fochon Biosciences, Ltd. | Compounds useful as kinase inhibitors |
TWI809489B (zh) * | 2020-09-10 | 2023-07-21 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
WO2022140246A1 (fr) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Procédés et composés destinés à l'autophagie ciblée |
WO2022228302A1 (fr) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Composés carboxamides hétéroaromatiques et leur utilisation |
BR112023021235A2 (pt) | 2021-05-14 | 2023-12-12 | Loxo Oncology Inc | Formas cocristalinas de um inibidor da tirosina quinase de bruton |
KR20240029070A (ko) * | 2021-07-01 | 2024-03-05 | 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 | 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용 |
CN115611810A (zh) * | 2021-07-16 | 2023-01-17 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
CA3241069A1 (fr) | 2021-12-14 | 2023-06-22 | Adrianus Petrus Antonius De Man | Inhibiteurs macrocycliques de btk |
WO2023143355A1 (fr) * | 2022-01-28 | 2023-08-03 | Hansoh Bio Llc | Dérivé d'amide d'azacycle, ses procédés de préparation et ses utilisations médicinales |
WO2023174397A1 (fr) * | 2022-03-18 | 2023-09-21 | Insilico Medicine Ip Limited | Inhibiteurs de kinase inhibitrice de cdc2 spécifique de la tyrosine et de la thréonine associés à une membrane de pyrazole (pkmyt1) et leurs utilisations |
CN115894376A (zh) * | 2022-12-15 | 2023-04-04 | 南京雷正医药科技有限公司 | 一种芳香族酰胺类化合物、药物组合物及其用途 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
NZ517758A (en) | 1999-09-17 | 2004-06-25 | Abbott Gmbh & Co | Pyrazolopyrimidines useful as therapeutic agents |
US6291504B1 (en) * | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
PT2526933E (pt) | 2006-09-22 | 2015-06-23 | Pharmacyclics Inc | Inibidores da tirosina-quinase de bruton |
MX2009003650A (es) * | 2006-10-06 | 2009-04-22 | Abbott Lab | Nuevos imidazotiazoles e imidazoxazoles. |
CA2668286C (fr) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Sonde d'activite de la tyrosine kinase de bruton et son procede d'utilisation |
IL295053A (en) | 2007-03-28 | 2022-09-01 | Pharmacyclics Llc | Broton tyrosine kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
NZ624345A (en) | 2008-06-27 | 2016-07-29 | Celgene Avilomics Res Inc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AU2009270856B2 (en) | 2008-07-16 | 2013-07-25 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors |
CN102105459B (zh) * | 2008-07-24 | 2014-09-10 | 内尔维阿诺医学科学有限公司 | 作为蛋白激酶抑制剂的3,4-二芳基吡唑类 |
US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
DK2588465T3 (en) * | 2010-06-30 | 2017-05-01 | Ironwood Pharmaceuticals Inc | SGC stimulators |
SI2710005T1 (sl) | 2011-05-17 | 2017-03-31 | Principia Biopharma Inc. | Zaviralci tirozinske kinaze |
US9580427B2 (en) | 2011-05-17 | 2017-02-28 | The Regents Of The University Of California | Kinase inhibitors |
WO2013010136A2 (fr) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibiteurs de tyrosine kinase de bruton |
EP2548877A1 (fr) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US20160045503A1 (en) | 2012-06-18 | 2016-02-18 | Principia Biopharma Inc. | Formulations containing reversible covalent compounds |
WO2014022569A1 (fr) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Traitement de la sécheresse oculaire |
AU2013299557B2 (en) * | 2012-08-10 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors |
GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
AU2013340345B2 (en) * | 2012-11-02 | 2016-10-27 | Pfizer Inc. | Bruton's tyrosine kinase inhibitors |
CN103848810A (zh) | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
MX2016004030A (es) * | 2013-09-30 | 2016-10-26 | Beijing Synercare Pharma Tech Co Ltd | Inhibidores sustituidos de nicotinamida de btk y su preparacion y uso en el tratamiento del cancer, inflamacion y enfermedad autoinmune. |
WO2015075051A1 (fr) * | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Inhibiteurs allostériques de protéines kinases c atypiques |
WO2015095099A1 (fr) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Inhibiteurs de btk |
CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
GB201404987D0 (en) * | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
WO2016120196A1 (fr) | 2015-01-28 | 2016-08-04 | Bayer Pharma Aktiengesellschaft | Dérivés de 4h-pyrrolo[3,2-c]pyridin-4-one |
GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
AU2016322063A1 (en) | 2015-09-16 | 2018-04-12 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP6948322B2 (ja) | 2015-12-16 | 2021-10-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン |
MX2018007422A (es) | 2015-12-16 | 2018-08-15 | Ecolab Usa Inc | Composiciones de acido peroxiformico para limpieza por filtracion en membrana. |
RS62525B1 (sr) | 2015-12-16 | 2021-11-30 | Boehringer Ingelheim Int | Bipirazolil derivati korisni za lečenje autoimunih oboljenja |
CA3008488C (fr) * | 2015-12-16 | 2023-10-10 | Loxo Oncology, Inc. | Composes utilises comme inhibiteurs de kinase |
US10981858B2 (en) | 2015-12-16 | 2021-04-20 | Priostar Pty Ltd | Dendrimer and formulations thereof |
-
2016
- 2016-12-16 CA CA3008488A patent/CA3008488C/fr active Active
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
- 2016-12-16 MX MX2021003478A patent/MX2021003478A/es unknown
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/fr active Application Filing
- 2016-12-16 CN CN202210311995.8A patent/CN114634447A/zh active Pending
- 2016-12-16 CN CN202111022492.0A patent/CN113636978A/zh active Pending
- 2016-12-16 RS RS20201291A patent/RS60982B1/sr unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 EP EP20194724.9A patent/EP3782994A1/fr active Pending
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 MX MX2018007267A patent/MX2018007267A/es unknown
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/fr active Active
- 2016-12-16 CN CN202210312064.XA patent/CN114605327A/zh active Pending
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko active Application Filing
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 CN CN202210312050.8A patent/CN114591242A/zh active Pending
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 CN CN202210311970.8A patent/CN114573510A/zh active Pending
- 2016-12-16 CN CN202111022488.4A patent/CN113603645A/zh active Pending
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active IP Right Grant
- 2016-12-16 CN CN202210310724.0A patent/CN114716381A/zh active Pending
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
-
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
- 2018-11-06 HK HK18114157.0A patent/HK1263254A1/zh unknown
-
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-11-19 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
-
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
-
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
-
2023
- 2023-07-31 US US18/362,249 patent/US20230372298A1/en active Pending
-
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I1/fr active Active
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR24C1009I1 (fr) | Composés utilisés comme inhibiteurs de kinase | |
MA52119A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA46045A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA45669A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA44860A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
MA45116A (fr) | Composés hétérocycliques comme immunomodulateurs | |
DK3656769T3 (da) | Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor | |
MA51229A (fr) | Hétérocycles bicycliques utilisés comme inhibiteurs des fgfr | |
MA44112A (fr) | Composés inhibiteurs de kinases se liant à tank | |
MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
MA42923A (fr) | Composés bicycliques comme inhibiteurs mixtes de atx/ca | |
MA42293A (fr) | Composés antibactériens | |
DK3303348T3 (da) | Naphthyridinforbindelser som JAK-kinaseinhibitorer | |
MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
MA41614A (fr) | Composés antiviraux | |
DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
MA41677A (fr) | Composés alpha-cinnamide et compositions comme inhibiteurs de hdac8 | |
MA41803A (fr) | Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques | |
DK3717488T3 (da) | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer | |
DK3130592T3 (da) | ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER | |
MA50537A (fr) | Composés deutérés utilisés comme immunomodulateurs | |
MA51221A (fr) | Composés de pyrazolopyridinone | |
MA43791A (fr) | Composés de carbapénème | |
ITUA20161990A1 (it) | Mangiatoia per avicoltura |